Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

NCT01384747 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

186

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Fimasartan
DRUG: Placebo

Sponsor

Seung-Jung Park

Collaborators

[object Object]
[object Object]